Immune changes in XXXX with @entity0 undergoing chemotherapy with @entity6023 .

@entity1 @entity650 @entity137 @entity6023 @entity0 @entity2841 @entity1356 @entity5 @entity310 @entity1421 @entity308 @entity1311 @entity3907 @entity665 @entity379 @entity1199 @entity10086 @entity1205
Besides @entity137 , @entity6023 induce other biological effects, especially in the immune system. @entity6023 have demonstrated immunostimulatory effects against @entity5 , supporting the idea that these agents suppress @entity5 through several mechanisms and not solely through inhibiting cell division. The purpose of the present study was to evaluate the effect of @entity6023 ( @entity1311 and @entity1205 ) and investigate their ability in alterating important immunological parameters in @entity0 @entity1 . Thirty @entity1 with @entity0 undergoing chemotherapy were randomly assigned into two groups treated with either single agent @entity1311 or @entity1205 . Sera from @entity1 before the first and after the last treatment cycle and from normal donors were assayed by ELISA for @entity1199 , @entity1356 , @entity379 , @entity2841 , @entity650 , @entity310 , and @entity1421 levels. In these same blood samples, NK and @entity10086 cell activity was tested in the total PBMC population against NK-sensitive K562 @entity5 targets, respectively, and autologous mixed lymphocyte reaction was tested by @entity665 proliferation assays. All @entity1 in both groups responded to therapy. Significant differences were observed in the following immune parameters between the control group of healthy blood donors and the pretreatment values of both @entity3907 groups; @entity1199 , @entity2841 , @entity379 levels and NK and @entity10086 cell @entity137 were @entity308 , whereas @entity310 and @entity650 levels were raised in @entity0 @entity1 before treatment compared to controls. There were no significant differences between the two treatment groups regarding any of the parameters studied. Both drugs led to increases in MLR values, NK and @entity10086 cell @entity137 , and @entity650 , @entity2841 , @entity379 levels, and decreases for @entity1356 , TNF, and @entity1421 levels. The percentage of these differences was greater for @entity1205 in comparison to @entity1311 (P<0.0001). More specifically, @entity1205 demonstrated a more pronounced effect on enhancing MLR, NK, @entity10086 activity and @entity379 , @entity1199 , @entity650 , and @entity2841 levels, as well as caused more potent reduction in @entity1356 and @entity310 levels when compared to @entity1311 . The present study indicates that @entity1 responded to treatment of @entity0 with single-agent @entity1311 or @entity1205 leads to an increase in serum @entity379 , @entity1199 , @entity650 , @entity2841 cytokine levels and enhancement of PBMC NK and @entity10086 cell activity, while they both lead to a decrease of acute phase serum cytokine levels of @entity1356 and @entity310 . Moreover, the effects of @entity1205 are in all the above parameters more pronounced than those of @entity1311 .
